Intellia Therapeutics (NTLA) Equity Ratio (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Equity Ratio data on file, last reported at 0.82 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.82, up 3.47% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.82 (up 3.47% YoY), and the FY2025 annual result was 0.8, up 8.9% from the prior year.
• Equity Ratio advanced to 0.82 in Q1 2026 per NTLA's latest filing, from 0.8 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.84 in Q1 2023 and troughed at 0.73 in Q4 2024.
• A 5-year average of 0.8 and a median of 0.81 in 2025 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio rose 9.68% in 2023, then slipped 9.3% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.81 in 2022, then decreased by 0.69% to 0.81 in 2023, then retreated by 9.3% to 0.73 in 2024, then grew by 8.9% to 0.8 in 2025, then gained by 2.64% to 0.82 in 2026.
• Business Quant data shows NTLA's Equity Ratio at 0.82 in Q1 2026, 0.8 in Q4 2025, and 0.81 in Q3 2025.